Osborne MSK Personal Statement
I have developed a strong interest in cancer health disparities—specifically, the genetic and socioeconomic causes for the uneven burden of prostate cancer mortality. Accordingly, my long-term goal is to promote health equity by way of molecular imaging probe development and applied genomics research. My belief is that the benefits of precision medicine, e.g., the responsible translation of theragnostic agents for prostate cancer, can play a critical role in addressing the disproportionate burden of prostate cancer mortality. Asking provocative questions, enhancing diversity in clinical trial participants, and advancing technological developments at the world-premiere cancer center is the best platform in which to further these efforts.
Osborne Lab for Cancer Health Equity Statement
The Osborne Laboratory for Cancer Health Equity has a strong interest in the genetic and socioeconomic causes of the uneven burden of cancer-related mortality. As it is now known that specific tumor genomic mutations can be exploited for more effective diagnosis and treatment, we will further explore how this is reflected in various subpopulations. We believe that this novel approach will have a significant impact on our patients. From the diagnostic perspective, we will continue to have a strong focus on the next generation of molecular imaging probes, but will focus on finding means of cost-effective and practical integration. It is our belief that cost effective diagnostics will translate to broader access to more effective therapeutics. Cancer equity will be addressed by combining these seemingly disparate areas of focus into one goal, dedicated towards the responsible translation of investigational compounds and genomic biomarkers into the communities most at-risk.
If you would like to additional information, contact us at (212) 639-7788.